TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6701692

Group type: EXPERIMENTAL
Intervention: Pre‐operative intracavitary caesium‐137 followed by a Wertheim hysterectomy (group 1)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Staging laparotomy with biopsy of suspicious lymph nodes (group 2)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Postoperative irradiation for patients with tumour invasion of the parametrium
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Postoperative irradiation for patients with tumour invasion of pelvic lymph nodes
Number of subjects: 92
Study: 31208463

Group type: EXPERIMENTAL
Intervention: Randomization restrictions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pre-randomization power distribution examination
Number of subjects: 0
Study: 28786530

Group type: EXPERIMENTAL
Intervention: Teneligliptin (20 mg) added to canagliflozin (C + T group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo added to canagliflozin (C + P group)
Number of subjects: 0
Study: 27165661

Group type: EXPERIMENTAL
Intervention: Khat (juice mixed with 45 g of ground khat leaves)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (33 ml of fruit juice)
Number of subjects: 21
Study: 23595769

Group type: EXPERIMENTAL
Intervention: Double-bundle ACL reconstruction (Group DB)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Single-bundle ACL reconstruction (Group SB)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Both techniques (DB and SB)
Number of subjects: 108
Study: 23036877

Group type: EXPERIMENTAL
Intervention: Medical exercise therapy (MET)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Arthroscopic surgery
Number of subjects: 17
Study: 20375180

Group type: EXPERIMENTAL
Intervention: CJ-13,610 (30 mg single oral dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ketoconazole (as an inhibitor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single-species allometric scaling from dog pharmacokinetic studies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single-species allometric scaling from rat pharmacokinetic studies
Number of subjects: 0
Study: 17822770

Group type: EXPERIMENTAL
Intervention: Voriconazole 200 mg twice daily
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 16286177

Group type: EXPERIMENTAL
Intervention: Rhythm-control antiarrhythmic drugs
Number of subjects: 245

Group type: COMPARATOR
Intervention: Rate-controlling drugs
Number of subjects: 245
Study: 12358651

Group type: EXPERIMENTAL
Intervention: Timed re-expansion inspiratory manoeuvre (TRIM) for 3 min
Number of subjects: 20

Group type: COMPARATOR
Intervention: 100% oxygen for 3 min
Number of subjects: 20
Study: 10397563

Group type: EXPERIMENTAL
Intervention: d4T plus 3TC (300 mg/day)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: ddl plus 3TC (300 mg/day)
Number of subjects: 299
Study: 7547093

Group type: EXPERIMENTAL
Intervention: Tenidap sodium 120 mg day‐1
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 1963170

Group type: EXPERIMENTAL
Intervention: MCP (10 mg in an intravenous bolus)
Number of subjects: 27

Group type: COMPARATOR
Intervention: MCP with bromocriptine (5 mg p.o. 3 h before MCP)
Number of subjects: 27

Group type: COMPARATOR
Intervention: MCP with atropine (1.2 mg in an intravenous bolus just before MCP)
Number of subjects: 27

Group type: COMPARATOR
Intervention: MCP with pirenzepine (40 mg in an intravenous bolus 10 min before MCP)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: MCP with metergoline (10 mg/day p.o. in 5 divided doses for 4 days before MCP)
Number of subjects: 27

Group type: COMPARATOR
Intervention: MCP with ketanserin (10 mg as a slow 3-min intravenous injection, 5 min before MCP)
Number of subjects: 27
Study: 7074794

Group type: EXPERIMENTAL
Intervention: verapamil (480 mg/day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: propranolol (160-320 mg/day)
Number of subjects: 16
Study: 30855472

Group type: EXPERIMENTAL
Intervention: Variable-rate feedback infusion plus demand dosing
Number of subjects: 78

Group type: COMPARATOR
Intervention: Constant-rate background infusion plus demand dosing
Number of subjects: 78
Study: 30229712

Group type: EXPERIMENTAL
Intervention: Beetroot juice (BJ) 140 ml
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 12
Study: 27417659

Group type: EXPERIMENTAL
Intervention: Home visits focused on infant feeding
Number of subjects: 1043
Study: 25165486

Group type: EXPERIMENTAL
Intervention: Path-counting formulas for generalized kinship coefficients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Recursive method for computing condensed identity coefficients
Number of subjects: 0
Study: 21892677

Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg every 6 months
Number of subjects: 7808

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7808
Study: 19022653

Group type: EXPERIMENTAL
Intervention: PCEA (Patient-Controlled Epidural Analgesia)
Number of subjects: 66

Group type: COMPARATOR
Intervention: PCEA + CBI (Continuous Background Infusion)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: PCEA
Number of subjects: 66

Group type: COMPARATOR
Intervention: PCEA + CBI
Number of subjects: 66
Study: 17228021

Group type: EXPERIMENTAL
Intervention: CHOP plus involved-field radiotherapy
Number of subjects: 576

Group type: COMPARATOR
Intervention: CHOP alone
Number of subjects: 576
Study: 15277962

Group type: EXPERIMENTAL
Intervention: Pneumotachograph (PCFp)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Portable peak flow meter (PCFm)
Number of subjects: 62
Study: 11939614

Group type: EXPERIMENTAL
Intervention: Red wine containing alcohol (0.8 g/kg)
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Excessive alcohol consumption (>21 units/week)
Number of subjects: 324

Group type: COMPARATOR
Intervention: Dealcoholized wine
Number of subjects: 324
Study: 9637639

Group type: EXPERIMENTAL
Intervention: Angiotensin II infusion (2.5 microg/ml, 10 ng x kg(‐1) x min(‐1))
Number of subjects: 54

Group type: COMPARATOR
Intervention: Ephedrine infusion (5 mg/ml, 50 microg x kg(‐1) x min(‐1))
Number of subjects: 54
Study: 7726544

Group type: EXPERIMENTAL
Intervention: Milk served at lunch for 3 months (Intervention group)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Water served at lunch (Control group)
Number of subjects: 147
Study: 2574194

Group type: EXPERIMENTAL
Intervention: Bromocriptine (N = 11)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (N = 5)
Number of subjects: 16
Study: 31424235

Group type: EXPERIMENTAL
Intervention: Romance narrative
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Sexual narrative
Number of subjects: 405

Group type: COMPARATOR
Intervention: Control narrative
Number of subjects: 405
Study: 30338365

Group type: EXPERIMENTAL
Intervention: Single-source dual-energy CT (SS-DECT)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Third-generation dual-source dual-energy CT (DS-DECT)
Number of subjects: 102

Group type: COMPARATOR
Intervention: DS-DECT
Number of subjects: 102
Study: 28490322

Group type: EXPERIMENTAL
Intervention: Video Game Therapy (VGT)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Balance Platform Therapy (BPT)
Number of subjects: 21
Study: 25155201

Group type: EXPERIMENTAL
Intervention: Ozil® mode
Number of subjects: 150

Group type: COMPARATOR
Intervention: US mode
Number of subjects: 150
Study: 23499982

Group type: EXPERIMENTAL
Intervention: The Blue Dog intervention (dog bite prevention and education program)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 21146460

Group type: EXPERIMENTAL
Intervention: CVD 909 vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ty21a vaccine
Number of subjects: 0
Study: 19534641

Group type: EXPERIMENTAL
Intervention: 5 ppm inspired NO
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 20 ppm inspired NO
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Inspired NO (5 ppm and 20 ppm)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (no NO gas)
Number of subjects: 15
Study: 16776759

Group type: EXPERIMENTAL
Intervention: Nd:YAG laser irradiation (1.5 W, 15 Hz, four times for 5 s)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indirect laser treatment (through a 1-mm-thick dentine disc)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Direct laser treatment
Number of subjects: 0
Study: 15338792

Group type: EXPERIMENTAL
Intervention: Diesel exhaust (DE) exposure (PM10 300 microg/m3)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Filtered air (control)
Number of subjects: 15
Study: 10648669

Group type: EXPERIMENTAL
Intervention: Meltspun cellulose diacetate
Number of subjects: 159

Group type: COMPARATOR
Intervention: High-flux polysulfone
Number of subjects: 159

Group type: COMPARATOR
Intervention: Low-flux polysulfone
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Severity of disease state (APACHE III score)
Number of subjects: 159
Study: 9262037

Group type: EXPERIMENTAL
Intervention: Tetrachlorodecaoxide (TCDO), 10 ml, twice daily, swish and swallow, for 7 days
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Tetrachlorodecaoxide (TCDO)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 8281391

Group type: EXPERIMENTAL
Intervention: Tomographic radionuclide ventriculography
Number of subjects: 100

Group type: COMPARATOR
Intervention: Planar imaging
Number of subjects: 100

Group type: COMPARATOR
Intervention: Angiography
Number of subjects: 100
Study: 2882626

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 1.5 g/day
Number of subjects: 505

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 505
Study: 29355409

Group type: EXPERIMENTAL
Intervention: Active CAMBRA treatment
Number of subjects: 460

Group type: COMPARATOR
Intervention: Standard of care (control)
Number of subjects: 460
Study: 27631750

Group type: EXPERIMENTAL
Intervention: Interrogative reminders (with or without reference to social context)
Number of subjects: 48091

Group type: COMPARATOR
Intervention: Noninterrogative reminders (with or without social context)
Number of subjects: 48091

Group type: COMPARATOR
Intervention: No-intervention control group
Number of subjects: 48091
Study: 24196274

Group type: EXPERIMENTAL
Intervention: Meal replacements (MRs)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Conventional reduced-fat diet (CD)
Number of subjects: 48
Study: 22825497

Group type: EXPERIMENTAL
Intervention: Micronutrient and probiotic yogurt (A)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Micronutrient alone yogurt (B)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Probiotic alone yogurt (C)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: All yogurt types
Number of subjects: 21
Study: 20516672

Group type: EXPERIMENTAL
Intervention: Antiplatelet medication
Number of subjects: 185

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Stroke patients
Number of subjects: 185
Study: 18484595

Group type: EXPERIMENTAL
Intervention: Irinotecan at a dose of 65 mg/m(2) plus cisplatin at a dose of 30 mg/m(2) (Arm A)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Gemcitabine at a dose of 900 mg/m(2) plus vinorelbine at a dose of 25 mg/m(2) (Arm B)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Irinotecan plus cisplatin (IP)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Gemcitabine plus vinorelbine (GV)
Number of subjects: 146
Study: 15911237

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa, 6.75 mug/kg, administered once every 3 weeks (asynchronous on day 15)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa, 6.75 mug/kg, administered once every 3 weeks (synchronous on day 1)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (both groups)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (synchronous administration)
Number of subjects: 81
Study: 12891541

Group type: EXPERIMENTAL
Intervention: Heater probe plus thrombin
Number of subjects: 247

Group type: COMPARATOR
Intervention: Heater probe plus placebo
Number of subjects: 247
Study: 10551056

Group type: EXPERIMENTAL
Intervention: Sevoflurane inhalation via nasal hood
Number of subjects: 24

Group type: COMPARATOR
Intervention: Midazolam and fentanyl intravenous sedation followed by propofol infusion
Number of subjects: 24
Study: 9051504

Group type: EXPERIMENTAL
Intervention: 3.0 mm tunnel incision
Number of subjects: 50

Group type: COMPARATOR
Intervention: 6.0 mm corneoscleral incision
Number of subjects: 50
Study: 1947515

Group type: EXPERIMENTAL
Intervention: Treatment as actually received
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intention to treat analysis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 6416259

Group type: EXPERIMENTAL
Intervention: Auranofin
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Gold Sodium Thiomalate (GST)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study: 31373890

Group type: COMPARATOR
Intervention: Conventional RBCs (Filtek Z350, Tetric N Ceram, Beautifil II)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Bulk-fill restorative RBCs (Filtek Bulk-Fill Restorative, Tetric N Ceram Bulk-Fill, Beautifil Bulk-Fill Restorative)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Flowable bulk-fill RBCs (Filtek Bulk-Fill Flowable, Tetric N Flow Bulk-Fill, Beautifil Bulk-Fill Flowable)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Conditioning in aqueous solutions (artificial saliva, 0.02 N citric acid, 50% ethanol-water solution)
Number of subjects: 10
Study: 31587046

Group type: EXPERIMENTAL
Intervention: CPAP plus usual care
Number of subjects: 1121

Group type: COMPARATOR
Intervention: Usual care (UC) alone
Number of subjects: 1121
Study: 28326568

Group type: EXPERIMENTAL
Intervention: eluxadoline 100 mg
Number of subjects: 2428

Group type: EXPERIMENTAL
Intervention: eluxadoline 75 mg
Number of subjects: 2428

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 2428
Study: 26381733

Group type: EXPERIMENTAL
Intervention: Active transcranial direct current stimulation (1 mA and 2 mA)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sham transcranial direct current stimulation
Number of subjects: 15
Study: 23725292

Group type: EXPERIMENTAL
Intervention: Dementia Care Mapping (DCM)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Comparison intervention using an alternative Qol assessment
Number of subjects: 9

Group type: COMPARATOR
Intervention: Already implemented DCM
Number of subjects: 9
Study: 21269421

Group type: COMPARATOR
Intervention: Conservative treatment (physical therapy, NSAIDs, subacromial infiltration with local anesthetic and corticosteroids if indicated)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgical reconstruction (acromioplasty with reconstruction of the rotator cuff tendon under general anesthesia and interscalenus plexus block)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both treatment modalities (surgical and conservative)
Number of subjects: 0
Study: 19782876

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 17374061

Group type: EXPERIMENTAL
Intervention: Expensive cream in luxury jar (Group A)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Regular moisturizer in luxury jar (Group B)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Expensive cream in neutral jar (Group C)
Number of subjects: 80
Study: 15309460

Group type: EXPERIMENTAL
Intervention: High-vegetable, fruit and fiber, low-fat diet intervention
Number of subjects: 52

Group type: COMPARATOR
Intervention: General dietary guidelines for cancer prevention (Control)
Number of subjects: 52
Study: 11915060

Group type: EXPERIMENTAL
Intervention: Continuous intrabursal infusion of 0.5% bupivacaine and 2 mg morphine (5 mL bolus and 40 mL maintenance at 0.5 mL/h)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline infusion (control group)
Number of subjects: 60
Study: 9549817

Group type: EXPERIMENTAL
Intervention: Methods for analysing incomplete longitudinal QOL data
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 7796496

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2099

Group type: EXPERIMENTAL
Intervention: Bolus c7E3 Fab
Number of subjects: 2099

Group type: EXPERIMENTAL
Intervention: Bolus plus infusion c7E3 Fab
Number of subjects: 2099
Study: 2194849

Group type: EXPERIMENTAL
Intervention: Topical application of monoethyl fumarate
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Systemic application of monoethyl fumarate
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Topical application of monoethyl fumarate in urticaria pigmentosa
Number of subjects: 12
Study: 694829

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Heparin analogue
Number of subjects: 200
Study: 30905157

Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum CCFM8610
Number of subjects: 0

Group type: COMPARATOR
Intervention: FXR agonist GW4064
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antibiotic pretreatment
Number of subjects: 0
Study: 28770482

Group type: EXPERIMENTAL
Intervention: Videoscopic inguinal lymphadenectomy (VIL)
Number of subjects: 102
Study: 25868829

Group type: EXPERIMENTAL
Intervention: DUO (endoscopic dual balloon system plus diet and exercise)
Number of subjects: 326

Group type: COMPARATOR
Intervention: DIET (sham endoscopy plus diet and exercise)
Number of subjects: 326
Study: 23370674

Group type: EXPERIMENTAL
Intervention: Acid infusion (1% HCl)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 14
Study: 20643386

Group type: EXPERIMENTAL
Intervention: Working memory representations guiding attention with a probability of valid cues at 20%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Working memory representations guiding attention with a probability of valid cues at 80%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Instructions given to participants
Number of subjects: 0
Study: 19661790

Group type: EXPERIMENTAL
Intervention: Therapeutic music video (TMV) intervention
Number of subjects: 12

Group type: COMPARATOR
Intervention: Audio-book protocol (Control)
Number of subjects: 12
Study: 17640582

Group type: EXPERIMENTAL
Intervention: Endoscopic procedures (balloon devices)
Number of subjects: 0
Study: 15573923

Group type: EXPERIMENTAL
Intervention: Air-filled balloon esophageal and anorectal catheters
Number of subjects: 10

Group type: COMPARATOR
Intervention: Solid-state esophageal catheter
Number of subjects: 10

Group type: COMPARATOR
Intervention: Water-perfused anorectal catheter
Number of subjects: 10
Study: 11564022

Group type: EXPERIMENTAL
Intervention: Laparoscopic colposuspension using Prolene mesh and titanium tacks
Number of subjects: 87

Group type: COMPARATOR
Intervention: Open Burch colposuspension
Number of subjects: 87
Study: 9773721

Group type: EXPERIMENTAL
Intervention: Insulin lispro (Humalog)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Regular human insulin (Humulin R)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control subjects (nondiabetic)
Number of subjects: 10
Study: 8145910

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) 0.4 g/kg body weight per day for 5 consecutive days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 3391879

Group type: EXPERIMENTAL
Intervention: Erythromycin acistrate (EA) 400 mg tid
Number of subjects: 183

Group type: COMPARATOR
Intervention: Enterocoated erythromycin base (EB) 500 mg tid
Number of subjects: 183
Study: 31489559

Group type: EXPERIMENTAL
Intervention: Telephone support intervention (two core calls in the week following an ED visit)
Number of subjects: 513

Group type: EXPERIMENTAL
Intervention: Telephone support intervention
Number of subjects: 513
Study: 30155718

Group type: EXPERIMENTAL
Intervention: Apabetalone
Number of subjects: 281

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 281
Study: 29269731

Group type: EXPERIMENTAL
Intervention: Very low-carbohydrate ketogenic (LCK) diet, n=16
Number of subjects: 34

Group type: COMPARATOR
Intervention: Moderate-carbohydrate, calorie-restricted, low-fat (MCCR) diet, n=18
Number of subjects: 34
Study: 25421366

Group type: EXPERIMENTAL
Intervention: Non-severe hypoglycaemic events in Type-1 diabetes
Number of subjects: 553

Group type: EXPERIMENTAL
Intervention: Non-severe hypoglycaemic events in Type-2 diabetes
Number of subjects: 553

Group type: EXPERIMENTAL
Intervention: Awareness of hypoglycaemic symptoms in Type-1 diabetes
Number of subjects: 553

Group type: EXPERIMENTAL
Intervention: Awareness of hypoglycaemic symptoms in Type-2 diabetes
Number of subjects: 553

Group type: EXPERIMENTAL
Intervention: Communication with physicians about hypoglycaemic events in Type-1 diabetes
Number of subjects: 553

Group type: EXPERIMENTAL
Intervention: Communication with physicians about hypoglycaemic events in Type-2 diabetes
Number of subjects: 553

Group type: EXPERIMENTAL
Intervention: Health-related impacts of hypoglycaemic events
Number of subjects: 553
Study: 23802562

Group type: EXPERIMENTAL
Intervention: Standardized information provided by gynecologists
Number of subjects: 9507
Study: 21443599

Group type: EXPERIMENTAL
Intervention: Alitretinoin 20 mg, once daily for 14 days
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Alitretinoin 40 mg, once daily for 14 days
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 24
Study: 19304097

Group type: EXPERIMENTAL
Intervention: Low vacuum group (vacuum 200 mm Hg, flow rate 20 cc/min)
Number of subjects: 60

Group type: COMPARATOR
Intervention: High vacuum group (vacuum 400 mm Hg, flow rate 40 cc/min)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Low vacuum group
Number of subjects: 60

Group type: COMPARATOR
Intervention: High vacuum group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 16387508

Group type: EXPERIMENTAL
Intervention: Blood cardioplegia (BC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Crystalloid cardioplegia (CC)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups (CC and BC)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Post-operative oxygen supplementation
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Overall comparison of CC and BC
Number of subjects: 30
Study: 14579980

Group type: EXPERIMENTAL
Intervention: WHO-ORS in group A (well nourished)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: WHO-ORS in group B (malnourished)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Hypokalaemia in group A (well nourished)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Hypokalaemia in group B (malnourished)
Number of subjects: 50